Potentiation of doxorubicin cytotoxicity by the calcium antagonist bepridil in anthracycline-resistant and-sensitive cell lines - A comparison with verapamil

Gerrit J. Schuurhuis, Henricus J. Broxterman, Jacobus J M van der Hoeven, Herbert M. Pinedo, Jan Lankelma

Research output: Contribution to journalArticle

Abstract

The ability of the calcium channel blocker bepridil (Bp) to potentiate doxorubicin (Dx) cytotoxicity and enhance its accumulation in anthracycline-sensitive and resistant human ovarian carcinoma cells (A2780 and 2780AD) and Chinese hamster ovarian (CHO) cells (AUXB1 and CHRC5) was compared with that of verapamil (Vp). A continuous exposure (48-72 h) to Bp as well as Vp potentiated Dx cytotoxicity in 2780AD cells. In shortterm incubations (2 h Dx and 4 h calcium channel blocker) the same effects were observed: 4 μM Bp (4Bp) and Vp (4Vp) were equipotent, but at concentrations of 1 and 2 μM, Vp was more active (4Vp=4Bp>2Vp>2Bp>1Vp>1Bp). In CHRC5 cells the corresponding sequence was: 4Vp>4Bp>2Vp>2Bp>1Vp>1Bp. At high (marginally inhibitory) concentrations, Bp and Vp reversed Dx resistance completely in CHRC5 cells and partly in 2780AD cells. No significant potentiation of Dx cytotoxicity by Bp or Vp was found in A2780 cells, but both were active in AUXB1 cells. In studies with radiolabelled Dx (2 μM), Bp and Vp (16.5 μM) stimulated accumulation in CHRC5 cells almost up to the level in AUXB1 cells. Dx accumulation in 2780AD cells (52 pmol/106 cells) could be stimulated to a maximum of about 90 pmol/106 cells (drug level in A2780 cells was 153 pmol/106 cells). Also, Bp- and Vp-induced stimulation of Dx accumulation was observed in AUXB1, but not in A2780 cells. Bp effected a dose-dependent inhibition of Dx efflux from preloaded 2780AD cells, but not from A2780 cells. We conclude that Bp is more effective than Vp in reversing resistance when both compounds are used in vitro at concentrations which are clinically achievable in plasma.

Original languageEnglish (US)
Pages (from-to)285-290
Number of pages6
JournalCancer Chemotherapy and Pharmacology
Volume20
Issue number4
DOIs
StatePublished - Dec 1987
Externally publishedYes

Fingerprint

Bepridil
Anthracyclines
Cytotoxicity
Verapamil
Doxorubicin
Cells
Calcium
Cell Line
Calcium Channel Blockers

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

Potentiation of doxorubicin cytotoxicity by the calcium antagonist bepridil in anthracycline-resistant and-sensitive cell lines - A comparison with verapamil. / Schuurhuis, Gerrit J.; Broxterman, Henricus J.; van der Hoeven, Jacobus J M; Pinedo, Herbert M.; Lankelma, Jan.

In: Cancer Chemotherapy and Pharmacology, Vol. 20, No. 4, 12.1987, p. 285-290.

Research output: Contribution to journalArticle

Schuurhuis, Gerrit J. ; Broxterman, Henricus J. ; van der Hoeven, Jacobus J M ; Pinedo, Herbert M. ; Lankelma, Jan. / Potentiation of doxorubicin cytotoxicity by the calcium antagonist bepridil in anthracycline-resistant and-sensitive cell lines - A comparison with verapamil. In: Cancer Chemotherapy and Pharmacology. 1987 ; Vol. 20, No. 4. pp. 285-290.
@article{954bc1c0e8814a539ab12bee9f4f78c0,
title = "Potentiation of doxorubicin cytotoxicity by the calcium antagonist bepridil in anthracycline-resistant and-sensitive cell lines - A comparison with verapamil",
abstract = "The ability of the calcium channel blocker bepridil (Bp) to potentiate doxorubicin (Dx) cytotoxicity and enhance its accumulation in anthracycline-sensitive and resistant human ovarian carcinoma cells (A2780 and 2780AD) and Chinese hamster ovarian (CHO) cells (AUXB1 and CHRC5) was compared with that of verapamil (Vp). A continuous exposure (48-72 h) to Bp as well as Vp potentiated Dx cytotoxicity in 2780AD cells. In shortterm incubations (2 h Dx and 4 h calcium channel blocker) the same effects were observed: 4 μM Bp (4Bp) and Vp (4Vp) were equipotent, but at concentrations of 1 and 2 μM, Vp was more active (4Vp=4Bp>2Vp>2Bp>1Vp>1Bp). In CHRC5 cells the corresponding sequence was: 4Vp>4Bp>2Vp>2Bp>1Vp>1Bp. At high (marginally inhibitory) concentrations, Bp and Vp reversed Dx resistance completely in CHRC5 cells and partly in 2780AD cells. No significant potentiation of Dx cytotoxicity by Bp or Vp was found in A2780 cells, but both were active in AUXB1 cells. In studies with radiolabelled Dx (2 μM), Bp and Vp (16.5 μM) stimulated accumulation in CHRC5 cells almost up to the level in AUXB1 cells. Dx accumulation in 2780AD cells (52 pmol/106 cells) could be stimulated to a maximum of about 90 pmol/106 cells (drug level in A2780 cells was 153 pmol/106 cells). Also, Bp- and Vp-induced stimulation of Dx accumulation was observed in AUXB1, but not in A2780 cells. Bp effected a dose-dependent inhibition of Dx efflux from preloaded 2780AD cells, but not from A2780 cells. We conclude that Bp is more effective than Vp in reversing resistance when both compounds are used in vitro at concentrations which are clinically achievable in plasma.",
author = "Schuurhuis, {Gerrit J.} and Broxterman, {Henricus J.} and {van der Hoeven}, {Jacobus J M} and Pinedo, {Herbert M.} and Jan Lankelma",
year = "1987",
month = "12",
doi = "10.1007/BF00262578",
language = "English (US)",
volume = "20",
pages = "285--290",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Potentiation of doxorubicin cytotoxicity by the calcium antagonist bepridil in anthracycline-resistant and-sensitive cell lines - A comparison with verapamil

AU - Schuurhuis, Gerrit J.

AU - Broxterman, Henricus J.

AU - van der Hoeven, Jacobus J M

AU - Pinedo, Herbert M.

AU - Lankelma, Jan

PY - 1987/12

Y1 - 1987/12

N2 - The ability of the calcium channel blocker bepridil (Bp) to potentiate doxorubicin (Dx) cytotoxicity and enhance its accumulation in anthracycline-sensitive and resistant human ovarian carcinoma cells (A2780 and 2780AD) and Chinese hamster ovarian (CHO) cells (AUXB1 and CHRC5) was compared with that of verapamil (Vp). A continuous exposure (48-72 h) to Bp as well as Vp potentiated Dx cytotoxicity in 2780AD cells. In shortterm incubations (2 h Dx and 4 h calcium channel blocker) the same effects were observed: 4 μM Bp (4Bp) and Vp (4Vp) were equipotent, but at concentrations of 1 and 2 μM, Vp was more active (4Vp=4Bp>2Vp>2Bp>1Vp>1Bp). In CHRC5 cells the corresponding sequence was: 4Vp>4Bp>2Vp>2Bp>1Vp>1Bp. At high (marginally inhibitory) concentrations, Bp and Vp reversed Dx resistance completely in CHRC5 cells and partly in 2780AD cells. No significant potentiation of Dx cytotoxicity by Bp or Vp was found in A2780 cells, but both were active in AUXB1 cells. In studies with radiolabelled Dx (2 μM), Bp and Vp (16.5 μM) stimulated accumulation in CHRC5 cells almost up to the level in AUXB1 cells. Dx accumulation in 2780AD cells (52 pmol/106 cells) could be stimulated to a maximum of about 90 pmol/106 cells (drug level in A2780 cells was 153 pmol/106 cells). Also, Bp- and Vp-induced stimulation of Dx accumulation was observed in AUXB1, but not in A2780 cells. Bp effected a dose-dependent inhibition of Dx efflux from preloaded 2780AD cells, but not from A2780 cells. We conclude that Bp is more effective than Vp in reversing resistance when both compounds are used in vitro at concentrations which are clinically achievable in plasma.

AB - The ability of the calcium channel blocker bepridil (Bp) to potentiate doxorubicin (Dx) cytotoxicity and enhance its accumulation in anthracycline-sensitive and resistant human ovarian carcinoma cells (A2780 and 2780AD) and Chinese hamster ovarian (CHO) cells (AUXB1 and CHRC5) was compared with that of verapamil (Vp). A continuous exposure (48-72 h) to Bp as well as Vp potentiated Dx cytotoxicity in 2780AD cells. In shortterm incubations (2 h Dx and 4 h calcium channel blocker) the same effects were observed: 4 μM Bp (4Bp) and Vp (4Vp) were equipotent, but at concentrations of 1 and 2 μM, Vp was more active (4Vp=4Bp>2Vp>2Bp>1Vp>1Bp). In CHRC5 cells the corresponding sequence was: 4Vp>4Bp>2Vp>2Bp>1Vp>1Bp. At high (marginally inhibitory) concentrations, Bp and Vp reversed Dx resistance completely in CHRC5 cells and partly in 2780AD cells. No significant potentiation of Dx cytotoxicity by Bp or Vp was found in A2780 cells, but both were active in AUXB1 cells. In studies with radiolabelled Dx (2 μM), Bp and Vp (16.5 μM) stimulated accumulation in CHRC5 cells almost up to the level in AUXB1 cells. Dx accumulation in 2780AD cells (52 pmol/106 cells) could be stimulated to a maximum of about 90 pmol/106 cells (drug level in A2780 cells was 153 pmol/106 cells). Also, Bp- and Vp-induced stimulation of Dx accumulation was observed in AUXB1, but not in A2780 cells. Bp effected a dose-dependent inhibition of Dx efflux from preloaded 2780AD cells, but not from A2780 cells. We conclude that Bp is more effective than Vp in reversing resistance when both compounds are used in vitro at concentrations which are clinically achievable in plasma.

UR - http://www.scopus.com/inward/record.url?scp=0023489699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023489699&partnerID=8YFLogxK

U2 - 10.1007/BF00262578

DO - 10.1007/BF00262578

M3 - Article

C2 - 3500807

AN - SCOPUS:0023489699

VL - 20

SP - 285

EP - 290

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 4

ER -